The Food and Drug Administration (FDA) has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody, for the treatment of celiac disease. Celiac disease ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and ...